What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing
Key Points
The transaction involved 48,842 shares with an estimated value of about $2.7 million.
This was a non-discretionary transaction executed to cover tax withholding obligations associated with the vesting of restricted stock units.
The remaining direct equity holdings are valued at $6.49 million based on the August 19 market close.
James William Rogers, the chief financial officer of Tempus AI, Inc. (NASDAQ:TEM), sold 48,842 shares of Class A Common Stock on August 18 and August 19, according to a recent SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $2.7 million |
| Shares sold (direct) | 48,842 |
| Post-transaction shares (directly held) | 106,024 |
| Post-transaction value | $6.49 million |
Transaction value based on SEC Form 4 weighted average sale price ($55.21); post-transaction value based on the August 19 market close ($61.25).
Key questions
- What was the primary driver of this transaction?
The disposition was a non-discretionary sell-to-cover event intended to satisfy statutory tax withholding requirements upon the vesting of restricted stock units. The activity was conducted under a Rule 10b5-1 trading plan adopted on September 11, 2025, and does not reflect a change in the insider's fundamental outlook on the company. - How much direct equity does the CFO retain?
Following this sale, James William Rogers retains direct ownership of 106,000 shares of Class A Common Stock. This position represents an insider ownership stake of roughly 0.06% of the company's outstanding equity. - What is the recent performance context for the stock?
As of the August 19 transaction date, the one-year total return for the stock was -16%. The transaction was executed at a weighted-average price of $55.21 per share, while the stock finished the August 19 session at $61.25. - What is the company's current financial profile?
Tempus AI, based in Chicago, operates in the healthcare information services industry with approximately 3,800 employees. The company reported trailing twelve-month revenue of $1.4 billion and a net loss of $254.4 million, maintaining a total market capitalization of $10.7 billion as of the latest data.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-08-19) | $61.25 |
| Market Capitalization | $10.7 billion |
| Revenue (TTM) | $1.4 billion |
| Net Income (TTM) | -$254.4 million |
Company Snapshot
- Tempus AI operates a closed-loop, full-stack healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue primarily through its diagnostic testing services and platform licensing.
- The company employs a technology-enabled laboratory services model that combines next-generation sequencing (NGS) testing with artificial intelligence-driven analytics to deliver actionable clinical insights to healthcare providers.
- Tempus AI serves physicians, healthcare systems, and diagnostic laboratories seeking advanced genomic testing and data analytics solutions, with particular focus on oncology and precision medicine applications.
Tempus AI is a healthcare technology company headquartered in Chicago, with approximately 3,800 employees, that has achieved $1.4 billion in TTM revenue while building a comprehensive platform integrating clinical diagnostics with AI-powered analytics. The company's competitive differentiation lies in its proprietary multimodal data repository and closed-loop integration between clinician workflows and laboratory capabilities, positioning it as a full-stack solution provider in precision medicine. Despite current net losses of $254.4 million TTM, the company maintains significant market valuation of $10.7 billion, reflecting investor confidence in its technology platform and market opportunity within healthcare information services.
What this transaction means for investors
Rogers's sale seems to run on the same 10b5-1 plan structure as the diagnostics chief's, adopted back in September 2025, and it split across August 18 and August 19 the same way, catching shares on both sides of the Moderna and Merck trial news that sent Tempus stock up 24% in a single session.
As CFO, Rogers is the one who effectively delivered the number that mattered most this quarter, Tempus's first GAAP profit. Net income came in at $5.6 million for the second quarter, helped by $98.5 million in unrealized gains on marketable securities, alongside revenue growth of 22% to $382.5 million. The company also raised full-year guidance to $1.6 billion and closed a $460 million convertible note offering during the quarter, fortifying the kind of balance sheet that funds a $1.5 billion acquisition without straining cash. That's what long-term investors should ultimately be paying more attention to than routine transactions like this one.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tempus AI. The Motley Fool has a disclosure policy.